![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
NC Trippodo, BC Panchal and M Fox
Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey.
Neutral endopeptidase inhibition (NEP-I) and angiotensin converting enzyme inhibition (ACE-I) act synergistically to produce acute beneficial hemodynamic effects in models of heart failure. Blockade of the formation of angiotensin II (Ang II) acting together with potentiation of the natriuretic peptides, bradykinin and other vasoactive peptides may mediate the interaction of dual enzyme inhibition. In this study, the potential roles of Ang II repression and bradykinin potentiation were evaluated in conscious cardiomyopathic hamsters with compensated heart failure. The Ang II AT1 receptor antagonist, SR 47436 (BMS-186295), was administered at 30 mumol/kg, i.v. followed by i.v. infusion at 1 mumol/kg/min in combination with NEP-I (SQ-28603 at 30 mumol/kg i.v.). Cardiac preload (left ventricular end diastolic pressure) and afterload (left ventricular systolic pressure) decreased significantly more after the combination of Ang II blockade and NEP-I than after either treatment alone. This indicated that repression of Ang II contributes importantly to the NEP-I/ACE-I interaction. Bradykinin B2 receptor antagonism by Hoe 140 at 100 micrograms/kg, i.v. significantly blunted the decrease in left ventricular end diastolic pressure but not the decrease in left ventricular systolic pressure after dual NEP-I/ACE-I (SQ-28603 and enalaprilat each at 30 mumol/kg, i.v.). This suggests that bradykinin potentiation contributes to the preload-reducing, but not the afterload- reducing, acute effects of NEP-I/ACE-I. Hence, both Ang II repression and bradykinin potentiation are factors contributing to the synergistic hemodynamic effects of combined NEP-I and ACE-I in hamsters with heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  J. C. M. Wait, N. Vaccharajani, J. Mitroka, M. Jemal, S. Khan, S. J. Bonacorsi, J. K. Rinehart, and R. A. Iyer METABOLISM OF [14C]GEMOPATRILAT AFTER ORAL ADMINISTRATION TO RATS, DOGS, AND HUMANS Drug Metab. Dispos., June 1, 2006; 34(6): 961 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Iyer, B. Malhotra, S. Khan, J. Mitroka, S. Bonacorsi Jr., S. C. Waller, J. K. Rinehart, and K. Kripalani Comparative Biotransformation of Radiolabeled [14C]Omapatrilat and Stable-labeled [13C2]Omapatrilat after Oral Administration to Rats, Dogs, and Humans Drug Metab. Dispos., January 1, 2003; 31(1): 67 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Schuijt, M. Basdew, R. van Veghel, R. de Vries, P. R. Saxena, R. G. Schoemaker, and A. H. Jan Danser AT2 receptor-mediated vasodilation in the heart: effect of myocardial infarction Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2590 - H2596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Campese, K. C. Lasseter, C. M. Ferrario, W. B. Smith, M. C. Ruddy, C. E. Grim, R. D. Smith, R. Vargas, M. F. Habashy, O. Vesterqvist, et al. Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients Hypertension, December 1, 2001; 38(6): 1342 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Quaschning, L. V. d'Uscio, S. Shaw, and T. F. Luscher Vasopeptidase Inhibition Exhibits Endothelial Protection in Salt-Induced Hypertension Hypertension, April 1, 2001; 37(4): 1108 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Arch Intern Med, March 12, 2001; 161(5): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Iyer, J. Mitroka, B. Malhotra, S. Bonacorsi Jr., S. C. Waller, J. K. Rinehart, V. A. Roongta, and K. Kripalani Metabolism of [14C]Omapatrilat, a Sulfhydryl-Containing Vasopeptidase Inhibitor in Humans Drug Metab. Dispos., January 1, 2001; 29(1): 60 - 69. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.-M. Duncan, G. M. James, F. Anastasopoulos, A. Kladis, T. A. Briscoe, and D. J. Campbell Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 295 - 303. [Abstract] [Full Text]
|
|
|
|
|
|
C. Marie, C. Mossiat, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction Cardiovasc Res, March 1, 1999; 41(3): 544 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, F. A. Recchia, R. Bernstein, X. Xu, A. Nasjletti, and T. H. Hintze Kinin-Mediated Coronary Nitric Oxide Production Contributes to the Therapeutic Action of Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitors and Amlodipine in the Treatment in Heart Failure J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 742 - 751. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Campbell, F. Anastasopoulos, A.-M. Duncan, G. M. James, A. Kladis, and T. A. Briscoe Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 567 - 577. [Abstract] [Full Text]
|
|
|
|
|
|
F. Anastasopoulos, R. Leung, A. Kladis, G. M. James, T. A. Briscoe, T. P. Gorski, and D. J. Campbell Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 799 - 805. [Abstract] [Full Text]
|
|
|
|
|
|
H. S. Margolius Kallikreins and Kinins : Some Unanswered Questions About System Characteristics and Roles in Human Disease Hypertension, August 1, 1995; 26(2): 221 - 229. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
